Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Portfolio Pulse from Vandana Singh
Four major pharmaceutical companies, Bristol Myers Squibb, Johnson & Johnson, AbbVie, and AstraZeneca, expect minimal business impact from upcoming Medicare price negotiations despite anticipated price cuts. Executives from these companies shared their perspectives during recent quarterly conference calls, indicating that the price cuts are manageable and in line with expectations.
July 30, 2024 | 6:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AbbVie expects minimal impact from Medicare price negotiations, with anticipated sales impact of Imbruvica already factored into forecasts.
AbbVie's CEO confirmed that the anticipated sales impact of Imbruvica due to Medicare price cuts has been factored into their forecasts, indicating minimal overall impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
AstraZeneca expects minimal impact from Medicare price negotiations due to competition from generic versions of its diabetes drug Farxiga.
An AstraZeneca executive indicated that the impact of Medicare price cuts will be minimal due to the expected competition from generic versions of Farxiga.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 100
NEUTRAL IMPACT
Bristol Myers Squibb expects minimal impact from Medicare price negotiations, with confidence in navigating the impact on its blood thinner Eliquis.
Bristol Myers Squibb's CEO expressed confidence in managing the impact of Medicare price cuts on Eliquis, indicating that the anticipated price reductions are in line with expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Johnson & Johnson maintains a positive long-term growth outlook despite expected discounts for Stelara and Xarelto due to Medicare price negotiations.
J&J executives indicated that the expected price cuts for Stelara and Xarelto are manageable and do not alter their positive long-term growth outlook.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100